How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,257 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

and Interventions Go to Arm Intervention/treatment Experimental: Remogen Device: Remogen instil 1 drop of the product in each eye, 4 times per day Active Comparator: Cationorm Device: Cationorm instil 1 drop of the product in each eye, 4 times per day Outcome Measures Go to Primary Outcome Measures : OSSF [ Time Frame: Day 28 ] Ocular surface staining with fluorescein (OSSF) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal (...) REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

122. Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

Experimental: Treatment lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day Drug: Lifitegrast Eye drop Other Name: Xiidra Outcome Measures Go to Primary Outcome Measures : Number of hours related to comfort in wearing contact lenses. [ Time Frame: Baseline to Week 12. ] The amount of comfortable lens wear time averaged over the 12th week of lens wear as reported with participant diary. Secondary Outcome Measures : Number of hours related to comfort in wearing contact (...) , the investigators may be able to relieve some of that discomfort. This study will enroll 50 subjects with contact lens discomfort and will receive lifitegrast to use over a period of approximately 3 months. Condition or disease Intervention/treatment Phase Contact Lens Dry Eye Drug: Lifitegrast Phase 4 Detailed Description: The most common reason for contact lens drop out is ocular discomfort, with patients identifying dryness as the major reason. Currently, many patients with contact lens dry eye (CLDE

2018 Clinical Trials

123. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction (Full text)

Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD).In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free (...) sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia

2018 International journal of ophthalmology PubMed

124. Immediate effect of a tear enhancer and meibomian gland expression on the corneal surface and whole eye higher order aberrations (Full text)

subjects (25 females, mean age±sd 32.5±11.0 years, and 25 males, 33.88±11.2 years) for two pupil sizes (3 and 6mm) in a dark environment. One drop of Blink Contacts™ (Abbott Medical Optics) was instilled into the right eye and HOA measurements repeated after 30s. After 1h, the meibomian glands of the left lower eyelid were gently squeezed and HOA measurements repeated after 30s.There was no significant difference for CS and WE root mean square (RMS) HOAs between right and left eyes before (both pupil (...) Immediate effect of a tear enhancer and meibomian gland expression on the corneal surface and whole eye higher order aberrations To investigate changes in higher order ocular aberrations (HOA) induced by the administration of 0.15% sodium hyaluronate tear enhancer (TE) and meibomian gland expression (ME) on the tear film of normal subjects.HOA values were obtained from the corneal surface (CS) and whole eye (WE), using a corneal topographer and Shack-Hartmann aberrometer, from both eyes of 50

2018 Journal of optometry PubMed

125. Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose (Full text)

).This was a double-masked, randomized, parallel-group study conducted in 14 clinical centers in Canada and Australia. Subjects with no more than mild dry eye instilled CMC-HA or CMC for 90 days post-LASIK. Ocular Surface Disease Index© (OSDI; primary efficacy measure), corneal staining, tear break-up time (TBUT), Schirmer's test, acceptability/tolerability surveys, and visual acuity were assessed at screening and days 2, 10, 30, 60, and 90 post-surgery. Safety analyses included all enrolled.A total of 148 (...) , reaching statistical significance at day 30 (P=0.013). Both treatments were well tolerated.CMC-HA-containing artificial tears relieved post-LASIK ocular dryness as well as CMC alone, and demonstrated incremental benefit in uncorrected vision, with a favorable safety profile. Results support use of CMC-HA eye drops to reduce signs and symptoms of ocular dryness post-LASIK.

2018 Clinical ophthalmology (Auckland, N.Z.) PubMed

126. Crosslinked Hyaluronic Acid With Liposomes and Crocin in Dry Eye

in a multi-dose container, it does not contain a preservative due to the dispenser that does not let microorganisms from outside. Contact lenses can be used while both lubricants are applied. In this regard, the study patients used their silicone hydrogel contact lenses monthly during the study. All patients in the study had a period of one month without using any type of artificial tear or eye drops. Once this time or study was over, the patients were explained how artificial tears should be instilled (...) Crosslinked Hyaluronic Acid With Liposomes and Crocin in Dry Eye Crosslinked Hyaluronic Acid With Liposomes and Crocin in Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Crosslinked Hyaluronic Acid

2018 Clinical Trials

127. Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

: Voclosporin Ophthalmic Solution Investigational Drug Other Name: 0.2% VOS Active Comparator: Comparator 0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days Drug: Restasis® Comparator Other Name: RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% Outcome Measures Go to Primary Outcome Measures : Drop Discomfort Assessment Visual Analogue Scale(VAS) [ Time Frame: 1-minute Post-Dose 1 instillation ] VAS scale 0 - 100 - Where 0 is the no discomfort and 100 the worst discomfort (...) excipients), topical anesthetics or vital dyes. Be unable to demonstrate correct instillation of over-the-counter (OTC) ocular lubricant. Report discomfort in both eyes from instillation of OTC ocular lubricant during Visit 2 (based on score of ≥30 on the Drop Discomfort VAS). Have used Restasis® (cyclosporine ophthalmic emulsion) within 30 days prior to Visit 1. Have used Restasis® for more than 1 month (if prior use is reported). Have used Xiidra® (lifitegrast ophthalmic solution) within 14 days prior

2018 Clinical Trials

128. Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease

using fluorescein, an ocular staining dye Secondary Outcome Measures : Change from baseline in dry eye symptom score at Day 1 [ Time Frame: Baseline, Day 1 ] As reported by the patient using a Likert scale post drop instillation Soothing sensation score [ Time Frame: Day 1 ] As reported by the patient using a Likert scale post drop instillation Tolerability assessment score [ Time Frame: Day 1 ] As reported by the patient using an assessment questionnaire post drop instillation Change from baseline (...) Phase Dry Eye Disease Other: Propylene glycol-based eye drops Not Applicable Detailed Description: Patients will attend 4 scheduled visits: Screening Visit (Day -7 to Day 0), Visit 1/Baseline Visit (Day 1), Visit 2 (Day 14) and Visit 3 (Day 28). This study is sponsored by Alcon, A Novartis Company. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 134 participants Intervention Model: Single Group Assignment Masking: None (Open

2018 Clinical Trials

129. Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery

tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks. Active Comparator: Preservative containing diquafosol group The subjects (...) solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks. Active Comparator: Preservative free sodium hyaluronate group The subjects use preservative

2018 Clinical Trials

130. Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye

Active Comparator: Autologous Serum 20% Treatment with Autologous Serum 20% for 2 months Drug: Autologous Serum 20% Instillation of 1 drop of Autologous Serum 20% four times a day Other Name: Autologus serum low concentration Active Comparator: Autologous Serum 50% Treatment with Autologous Serum 50% for 2 months Drug: Autologous Serum 50% Instillation of 1 drop of Autologous Serum 50% four times a day Other Name: Autologus serum high concentration Outcome Measures Go to Primary Outcome Measures (...) Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2018 Clinical Trials

131. Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

will then be determined. All pre-treatment assessments will be done at this visit. Randomization will occur. If randomized to receive Xiidra eye drops, a prescription will be written and the treatment will be started right away. If randomized to eyelash prostheses, then a second study visit will be made approximately 2 weeks later. Visit 2 (Eyelash Prostheses application) Subjects randomized to receive eyelash prostheses will have them applied approximately 2 weeks after the screening and randomization visit. Visit 3 (...) (Final visit) will be 3 weeks post eyelash prosthesis placement and 5 weeks post Xiidra eye drop initiation. This was done to compare the maximal treatment effect between the two groups. All subjects will undergo post-treatment assessments. At each visit, patients will be asked to report any adverse events. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Allocation: Randomized Intervention Model: Parallel

2018 Clinical Trials

132. [Walnut-shell moxibustion for dry eye symptoms: a randomized controlled trial]. (PubMed)

times a day, one drop instilled in each eye each time, for 4 weeks totally. At the baseline (before treatment) and in 4 weeks of treatment, the score of the ocular surface disease index (OSDI), the score of visual analogous scale (VAS) for eye symptoms, the tear film break-up time (BUT), the cornea fluorescent pigmentation (FL) and SchirmerⅠ(SchⅠ) were evaluated. In 1-month follow-up after treatment termination, the changes of OSDI and VAS scores were evaluated in the two groups.In 4 weeks (...) [Walnut-shell moxibustion for dry eye symptoms: a randomized controlled trial]. To evaluate the effects of walnut-shell moxibusiton on dry eye symptoms.A total of 67 patients with dry eye symptoms were randomized into a walnut moxibustion group and a sodium hyaluronate eye drops group.In the walnut moxibustion group, the walnut moxibustion was used, once every two days, 3 times a week, for 4 weeks totally. In the sodium hyaluronate eye drops group, sodium hyaluronate eye drops were selected, 4

2018 Zhongguo zhen jiu = Chinese acupuncture & moxibustion

133. Flicker electroretinograms of eyes with cataract recorded with RETeval system before and after mydriasis (Full text)

Flicker electroretinograms of eyes with cataract recorded with RETeval system before and after mydriasis The aim of this study is to determine the effect of pupil size of eyes with cataracts on the flicker electroretinograms (ERGs) elicited and recorded with the RETeval system.Forty-one eyes of 41 patients (mean age, 76.5±7.3 years) that had grade 2 nuclear or cortical cataract without any other abnormalities were studied. Flicker ERGs were recorded before and after mydriatic drops instillation (...) ). The mean amplitudes and implicit times of the nuclear and cortical cataracts groups before the mydriasis were also not significantly different from those after mydriasis for all stimulus intensities.The lack of significant differences in the amplitudes and the implicit times of the flicker ERG of cataractous eyes before and after mydriasis indicated that the RETeval flicker ERGs in cataractous eyes is less affected by the pupil diameter. With our earlier study, it was assumed that the effect

2018 Clinical ophthalmology (Auckland, N.Z.) PubMed

134. Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency (Full text)

% or 0.3% sodium hyaluronate (SH) eye drops by using the LipiView ocular surface interferometer.In the lipid deficiency group, the LLT increased from baseline at 1min post instillation. The LLT after the instillation of 0.1% SH was significantly higher than that after the instillation of 0.3% SH (P<0.001). The LLT returned to baseline at 15min post instillation of 0.1% SH and at 5min post instillation of 0.3% SH. In the non-lipid deficiency group, the LLT decreased from baseline at 1min and returned (...) Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency To investigate the effects of different concentrations of artificial tears on lipid layer thickness (LLT) and blink rate (BR) in dry eye patients.This study included 106 eyes of 58 patients with dry eye. The lipid deficiency type was defined as the LLT baseline <75 nm. The LLT and BR were measured at baseline and 1, 5 and 15min after the instillation of 0.1

2018 International journal of ophthalmology PubMed

135. A comparative study of Bilvadi Yoga Ashchyotana and eye drops in Vataja Abhishyanda (Simple Allergic Conjunctivitis). (Full text)

and it should be followed lifelong and Ayurveda can provide better relief in such manifestation. This is the first research study on Vataja Abhishyanda. Patients were selected from the Outpatient Department (OPD), Inpatient Department (IPD), of the Shalakya Tantra Department and were randomly divided into two groups. In Group-A Bilvadi Ashchyotana and in Group-B Bilvadi eye drops were instilled for three months. Total 32 patients were registered and 27 patients completed the course of treatment. Bilvadi (...) A comparative study of Bilvadi Yoga Ashchyotana and eye drops in Vataja Abhishyanda (Simple Allergic Conjunctivitis). Simple allergic conjunctivitis is the most common form of ocular allergy (prevalence 5 - 22 %). It is a hypersensitivity reaction to specific airborne antigens. The disease Vataja Abhishyanda, which is due to vitiation of Vata Pradhana Tridosha is comparable with this condition. The management of simple allergic conjunctivitis in modern ophthalmology is very expensive

2012 Ayu PubMed

136. Ocular Safety and Pharmacokinetics Study of FK506 Suspension Eye Drops After Corneal Transplantation (Full text)

Ocular Safety and Pharmacokinetics Study of FK506 Suspension Eye Drops After Corneal Transplantation The aim of this study was to investigate the sensitization, pharmacokinetics, and absorption of FK506 after corneal transplantation.New Zealand albino rabbits were divided into normal and corneal transplantation groups. Each group was divided into 5 subgroups--saline, blank matrix, high-dose, medium-dose, and low-dose, respectively. There were 10 rabbits in each subgroup. One drop (25 μL (...) and tissue distribution determination as the former 5 rabbits in each subgroup (the second batch).Fluorescein staining and local ocular reaction provided evidence that there were no significant differences between control and FK506-instilled eyes in the rabbit model at any of the tested doses. Histologic examination revealed no ocular abnormality in the rabbits instilled with any doses of FK506 eyedrop. The peak serum concentration (C(max)) of systemic absorption ranged from 4.31±0.79 ng/mL to 14.89±6.85

2012 Journal of Ocular Pharmacology and Therapeutics PubMed

137. Novel formulation of glycerin 1% artificial tears extends tear film break-up time compared with Systane lubricant eye drops. (PubMed)

) Lubricant Eye Drops; Alcon, Fort Worth, TX).This prospective single-center, single visit, randomized, double-masked exploratory trial compared the new formulation and Systane using TFBUT. Noninvasive break-up time (NIBUT) was measured in subjects with asymptomatic to mild (n=5), mild to moderate (n=5), and moderate to severe (n=6) dry eye disease using the TearscopePlus™ at pre-instillation and again at 15, 30, 60, and 120 min after instillation. Fluorescein break-up time (FBUT) was measured at 120 min (...) in improving the performance of demulcents to significantly prolong NIBUT at 15 min, and that protective activity from this artificial tear product for 2 or more hours after eye drop instillation is possible.

2012 Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

138. Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers (NGF0112) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01744704 Recruitment Status : Completed First Posted : December 7, 2012 Last Update Posted : May

2012 Clinical Trials

139. Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses

has been used in ophthalmology because of its mucolytic properties for several years. Based on theoretical considerations, one can hypothesize that the new chitosan derivative may show an increased adhesion to mucins of the ocular surface and may therefore be particularly beneficial in reducing the symptoms associated with DES. We have recently shown in a phase I trial that single instillation of chitosan-N-acetylcysteine eye drops is well tolerated in young healthy subjects. However, no data (...) is yet available about safety and tolerability of chitosan-N-acetylcysteine in subjects wearing contact lenses. This is of special interest because the tear film is critical to successful contact lens wear. Disturbances of the quantity or quality of the tear film results in intolerance of contact lens wear and possible damage to the ocular surface. This trial seeks to investigate the local tolerability and possible ocular discomfort of chitosan-N-acetylcysteine eye drops after repeated instillation

2012 Clinical Trials

140. Cyclosporine - Moderate to moderately severe dry eye disease

Canada-approved dose is one drop instilled twice a day in each eye, approximately 12 hours apart. Summary of CEDAC Considerations: The Committee considered the following information prepared by the Common Drug Review (CDR): a systematic review of RCTs of cyclosporine ophthalmic emulsion, a critique of the manufacturer’s pharmacoeconomic evaluation, and patient group-submitted information about outcomes and issues important to patients. Common Drug Review CEDAC Meeting – June 15, 2011 Notice of CEDAC (...) , painful, and sun- and wind-sensitive. • Patients provided examples of how their quality of life was affected by their reduced ability to read, watch television, drive, and participate in outside activities because of their dry eye disease. • Patients considered twice-daily application of cyclosporine ophthalmic suspension to be more convenient than artificial tears, which are commonly instilled many times per day. They mentioned adverse consequences of ophthalmic corticosteroids as a concern. Other

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>